If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Hormones such as androgen, prolactin, estrogen and progesterone have been shown to influence corneal biomechanics and tissue remodeling, potentially affecting the integrity of the cornea in individuals predisposed to keratoconus. Moreover, fluctuations in hormonal levels during puberty and pregnancy have been associated with the onset or exacerbation of keratoconus in some cases. Keratoconus has been associated with atopic diseases, which include asthma, allergies, and eczema, and it is not uncommon for several or all of these diseases to affect one person. Keratoconus is also associated with Alport syndrome, Down syndrome and Marfan syndrome. A number of studies suggest vigorous eye rubbing contributes to the progression of keratoconus, and people should be discouraged from the practice. Keratoconus differs from ectasia, which is caused by LASIK eye surgery. Post-LASIK Ectasia has been associated with the excessive removal of the eye's stromal bed tissue during surgery.
== Background == Crude oil contains sulfur in its composition, with the latter being the most abundant element after carbon and hydrogen. Depending on its source, the amount of sulfur present in crude oil can range from 0.05 to 10%. Accordingly, the oil can be classified as sweet or sour if the sulfur concentration is below or above 0.5%, respectively. The combustion of crude oil releases sulfur oxides (SOx) to the atmosphere, which are harmful to public health and contribute to serious environmental effects such as air pollution and acid rains. In addition, the sulfur content in crude oil is a major problem for refineries, as it promotes the corrosion of the equipment and the poisoning of the noble metal catalysts. The levels of sulfur in any oil field are too high for the fossil fuels derived from it (such as gasoline, diesel, or jet fuel ) to be used in combustion engines without pre-treatment to remove organosulfur compounds. The reduction of the concentration of sulfur in crude oil becomes necessary to mitigate one of the leading sources of the harmful health and environmental effects caused by its combustion. In this sense, the European Union has taken steps to decrease the sulfur content in diesel below 10 ppm, while the US has made efforts to restrict the sulfur content in diesel and gasoline to a maximum of 15 ppm. The reduction of sulfur compounds in oil fuels can be achieved by a process named desulfurization.
=== Early days of Pentagram === Though Pentagram struggled with lineup changes and financial issues, the band became a key influence in the development of doom metal, with Liebling's distinct vocals and songwriting playing a major role in their cult following. Their early recordings, particularly Relentless (1985) and Day of Reckoning (1987), laid the groundwork for future doom metal acts. Despite their potential, Liebling's struggles with substance abuse, internal conflicts, and frequent lineup changes prevented Pentagram from achieving stability and mainstream success. By the mid-1970s, the band had caught the attention of influential managers and producers. One such figure was Gordon Fletcher, a columnist for Rolling Stone and Creem, who connected them with Sandy Pearlman and Murray Krugman, producers and managers of Blue Öyster Cult. Pentagram had an opportunity to record a full album, but the deal collapsed when Liebling, dissatisfied with the production of one of his tracks, had a heated argument with Krugman. As a result, Krugman walked out, canceling their contract. Gene Simmons and Paul Stanley of Kiss were invited to a Pentagram rehearsal, with hopes of impressing them and securing their mentorship. However, guitarist Vince McAllister and bassist Greg Mayne, who at the time were janitors, arrived late, still in their dirty uniforms from work. The Kiss members mocked their appearance rather than taking the band seriously. Despite this, Paul Stanley offered to purchase some of their songs, but Liebling refused, wanting to keep control of his material.
Hemoglobin is a protein that transports oxygen in the blood. Genetic differences lead to structural variants in the hemoglobin protein structure. Some variants can cause disease while others have little to no effect. The normal hemoglobin types are Hemoglobin A (HbA), which makes up 95–98% of total hemoglobin in adults, Hemoglobin A2 (HbA2), which constitutes 2–3% of total hemoglobin in adults, and Hemoglobin F (HbF), which is the predominant hemoglobin in the fetus during pregnancy, and may persist in small amounts in adults. Hemoglobin variants occur when there are mutations in specific genes that code for the protein chains, known as globins, which make up the hemoglobin molecule. This leads to amino acid substitutions in the hemoglobin molecule that could affect the structure, properties, and/or the stability of the hemoglobin molecule. There are over 1,000 known mutations in the genes coding for hemoglobin in humans.
Sources: en.wikipedia.org
Bugs then shows Neo her crew in an abandoned theater. Morpheus, part of Bugs' group once again, offers a blue pill and a red pill to Neo, who takes the red pill. The team then "unplugs" Neo and with the help of a friendly machine, who was hacked, he is revived in the real world inside Bugs' ship, the Mnemosyne. In the real world, after Morpheus helps Neo regain his memories and fighting style, the Mnemosyne goes to Io, the last human city led by Niobe. Niobe reveals that, when Zion was nearly destroyed by the machines in another war, she and the rest of the inhabitants escaped and made a new city with the help of some machines. After sixty years, Niobe does not trust Neo, but lets the Mnemosyne crew destroy the Matrix with the help of Sati, the sentient program who helped Neo in Revolutions. In the Matrix, Neo's therapist, named the Analyst, a program designed to study the human psyche and the new leader of both the Matrix and the machines, explains that after Neo and Trinity's deaths, he was able to resurrect them to study them. He found that suppressing their memories but keeping them close to one another made the Matrix more power-efficient and more resistant to the anomalies that caused the previous iterations to fail. However, Neo's liberation destabilized the system and triggered a fail-safe to reboot the Matrix. The Analyst stalled the reboot by convincing his superiors that threatening to kill Trinity would get Neo to voluntarily return to his pod.
Dr. George D. Winter (1927–1981) was the British-born pioneer of moist wound healing. In 1962, while working at the Department of Biomechanics and Surgical Materials at the University of London, Winter published his landmark Nature paper Formation of the scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig (Nature 193:293 1962) where he demonstrated that, contrary to the conventional wisdom that wounds should be allowed to dry out and form scabs to promote healing, wounds instead healed faster if kept moist. Winter formed multiple partial thickness wounds on the backs of pigs, half left open to the air and half covered with a polymer film to keep them hydrated. The latter wounds healed faster, as measured by the migration of new epithelium on the wound bed. This work began the evolution of modern wound dressings that promote moist wound healing. George D. Winter was the first president of the European Society for Biomaterials and has an annual award named after him.
The data is from the year ending January 2, and market value is from March 11, 2011. In 2014, the chain was purchased by a foreign company, Brazilian firm 3G Capital, known for its ownership of Burger King. Despite foreign ownership, Tim Hortons remains a Canadian cultural phenomenon.
Sources: en.wikipedia.org
Oxygen primary ions are often used to investigate electropositive elements due to an increase of the generation probability of positive secondary ions, while caesium primary ions often are used when electronegative elements are being investigated. For short pulsed ion beams in static SIMS, LMIGs are most often deployed for analysis; they can be combined with either an oxygen gun or a caesium gun during elemental depth profiling, or with a C60+ or gas-cluster ion source during molecular depth profiling.
=== Compressor refrigerators === A vapor compression cycle is used in most household refrigerators, refrigerator–freezers and freezers. In this cycle, a circulating refrigerant such as R134a enters a compressor as low-pressure vapor at or slightly below the temperature of the refrigerator interior. The vapor is compressed and exits the compressor as high-pressure superheated vapor. The superheated vapor travels under pressure through coils or tubes that make up the condenser; the coils or tubes are passively cooled by exposure to air in the room. The condenser cools the vapor, which liquefies. As the refrigerant leaves the condenser, it is still under pressure but is now only slightly above room temperature. This liquid refrigerant is forced through a metering or throttling device, also known as an expansion valve (essentially a pin-hole sized constriction in the tubing) to an area of much lower pressure. The sudden decrease in pressure results in explosive-like flash evaporation of a portion (typically about half) of the liquid. The latent heat absorbed by this flash evaporation is drawn mostly from adjacent still-liquid refrigerant, a phenomenon known as auto-refrigeration. This cold and partially vaporized refrigerant continues through the coils or tubes of the evaporator unit. A fan blows air from the compartment ("box air") across these coils or tubes and the refrigerant completely vaporizes, drawing further latent heat from the box air. This cooled air is returned to the refrigerator or freezer compartment, and so keeps the box air cold.
In Japan, an herb sprinkling powder on rice or other food has long been called furikake. For example, an article titled "Picnic Bento" published in 1925 describes how to make onigiri: "Make a small onigiri of warm rice and furikake a little roasted-sesame on it." The term furikake became established in the 1950s, but there were equivalent foods to it even before that. The 13th-century culinary treatise "Chujiruiki" (厨事類記) lists shredded and dried red seabream, salmon, and shark meat, as well as thin slices of katsuobushi, as garnishes for rice. Gomashio, which is still commonly eaten today, is made by roasting sesame seeds and mixing them with baked salt, and appears in an ancient document, Diary of Ishiyama Hongan-ji at 1536, under the name "gomashio." In that document, it is written that "on March 3, sekihan (red rice) was served at the celebration, and gomashio was placed on top of it."
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.